Peripheral Angioedema and Upper Airway Edema in Young Woman

Gargantilla Madera P*, García Tobaruela A and Belda Bilbao L

Department of Internal Medicine, University Francisco of Vitoria, Spain

*Corresponding author: Pedro Gargantilla, Department of Internal Medicine, Hospital of El Escorial Madrid, University Francisco of Vitoria, Spain, E-mail: pgargantillam@gmail.com

Keywords

Angioedema, Autoimmunity, Acquired angioedema, Hereditary angioedema, Angioneurotic edema, Acquired C1 inhibitor, C1 inhibitor protein

C1 inhibitor (C1-INH) deficiency is a rare syndrome clinically characterized by recurrent localized and self-limiting acute edema episodes in different locations [1] or angioedema without urticaria. It can involve the skin, upper respiratory airways and abdomen.

There are two main types: Hereditary (C1-INH-HAE) and acquired (C1-INH-AAE). We present the clinical characteristics of a patient with angioedema secondary to C1-INH-AAE type II.

A 38-year-old woman, without family history of angioedema, suffered several self-limiting acute edema episodes (localized in upper/lower limbs). One month after, she presented an upper airway edema associated with glottis edema, which was treated in emergency department with corticosteroids, without improvement.

Routine blood tests performed were normal, but the immunological study revealed low C4 concentrations (2.6 mg/dL), normal antigenic C1-INH (14.2 mg/dL), low C1-INH function (25.7%), normal serum C1q (157.95 µg/dL) and presence of anti-C1-INH IgG autoantibodies. Sequencing of the C1-INH and F12 genes revealed no pathogenic variants. She was treated with 1000 units of C1 inhibitor plasma concentrate (Bertinert, CSL-Behring) with a good response and no adverse events.

We report the case of a patient who developed C1-INH-AAE. Our initial diagnosis was C1-INH-HAE, since the mutation in the C1-INH gene is not found in 5-10% of families with C1-INH-AAE and up to 25% of patients can have a spontaneous mutation [2]. But positive anti-C1-INH antibodies enabled us to make a more accurate diagnosis of C1-INH-AAE type II.

This disease was first described by Caldwell, et al. in 1972 and it is due to deficiency of C1 esterase inhibitor, hyperactivation of the classical pathway of human complement and angioedema symptoms mediated by bradykinin released by inappropriate activation of the contact-kinin system [3].

The annual incidence is 1.09 individuals per 100,000 inhabitants in Spain and the onset of C1-INH-AAE is most common after the fourth decade of life. Persons of any race can be affected by C1-INH-AAE. Men and women are equally affected.

C1-INH-AAE, much less prevalent than C1-INH-HAE, and is often associated with lymphoproliferative disorders (type I) and/or the presence of anti-C1-INH autoantibodies (type II) [1].

C1-INH-AAE is first suspected in patients aged 40 or above who present with recurrent cutaneous and/or mucosal angioedema without urticaria, without an evident triggering factor, and without family history of angioedema.

The edema produced in C1-INH-AAE has been linked to the release of kinins, their activation leads to vascular leakage, which accounts for the typical non-puritic, non-urticarious, and non-erythematous edema of C1-INH-AAE in contrast to the traditional histamine-associated itchy wheal and flare presentation of allergic edema.

The clinical presentation mostly involves peripheral angioedema of the head, neck and extremities, fol-
A small percentage of patients with C1-INH AAE become less responsive to C1-INHRP over time, requiring higher doses to control symptoms. In these patients we must to use the newer therapies for bradykinin-mediated angioedema (ecallantide and icatibant) [5]. Rituximab can be an alternative treatment in cases of C1-INH-AAE associated with C1-INH autoantibodies.

Angioedema prophylaxis is performed using antifibrinolytic agents and attenuated androgens (stanozolol, danazol) with antifibrinolytic agents providing somewhat better results [2].

References